Update on Licensed Oncology Product in China

Summary by AI BETAClose X

HUTCHMED announced the voluntary withdrawal and product recall of its licensed oncology product TAZVERIK® (tazemetostat) in China, Hong Kong, and Macau, following a decision by Ipsen due to emerging data from the SYMPHONY-1 trial indicating that risks of secondary hematologic malignancies may outweigh potential benefits. Consequently, all active tazemetostat clinical trials are being discontinued. Despite this withdrawal, HUTCHMED stated that it does not expect the event to impact its financial guidance, noting that TAZVERIK® sales in 2025 were US$2.5 million.

Disclaimer*

UK 100

Latest directors dealings